自体显微乳房再造中化学预防的时机
该回顾性研究比较了2010年8月至2016年7月间196例(311皮瓣)自体显微乳房再造患者术前与术后启动依诺肝素化学预防的出血并发症。结果显示术前组血肿清除率1%,术后组输血率4.4%,两组均无静脉血栓栓塞事件,提示术前化学预防可安全使用。
要点
- 术前依诺肝素40mg不增加血肿清除风险
- 术后启动化学预防可能因药物起效时间增加渗血
- 两组均未发生静脉血栓栓塞事件
核心结论
- 术前化学预防在显微乳房再造患者中可安全使用。
- 术后组出血率较高可能与依诺肝素4至6小时起效有关。
研究设计与样本
- 回顾性病历 review,2010年8月至2016年7月。
- 2013年化学预防启动时机由术后改为术前,分为两组。
- 共196例患者(311皮瓣):术前组105例(166皮瓣),术后组91例(145皮瓣)。
主要发现
- 5例需血肿清除(2.6%),其中术前组1例(1%)。
- 7例接受输血:术前组3例,术后组4例(2.9% vs 4.4%;p=0.419)。
- 共1例皮瓣失败,两组均无静脉血栓栓塞事件记录。
关键数值与推荐
- 术前组接受依诺肝素40mg。
- 依诺肝素起效时间为4至6小时。
临床怎么用
- 可考虑术前启动依诺肝素40mg化学预防。
- 需关注术后渗血风险,尤其术后给药时。
局限性
- 回顾性设计,证据等级为治疗性III级。
- 样本量有限,事件数较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing autologous breast reconstruction are at high risk of perioperative venous thromboembolic events. The efficacy of chemoprophylaxis in decreasing venous thromboembolic events is well established, but the timing of chemoprophylaxis remains controversial. The authors compare the incidence of bleeding following preoperative versus postoperative initiation of chemoprophylaxis in microvascular breast reconstruction. METHODS: A retrospective chart review was performed from August of 2010 to July of 2016. Initiation of chemoprophylaxis changed from postoperative to preoperative in 2013, dividing subjects into two groups. Patient demographics, comorbidities, and complications were reviewed. RESULTS: A total of 196 patients (311 flaps) were included in the study. A total of 105 patients (166 flaps) received preoperative enoxaparin (40 mg) and 91 patients (145 flaps) received postoperative chemoprophylaxis. A total of five patients required hematoma evacuation (2.6 percent). Of these, one hematoma (1 percent) occurred in the preoperative chemoprophylaxis group. Seven patients received blood transfusions: three in the preoperative group and four in the postoperative group (2.9 percent versus 4.4 percent; p = 0.419). There was a total of one flap failure, and there were no documented venous thromboembolic events in any of the groups. CONCLUSIONS: This study demonstrates that preoperative chemoprophylaxis can be used safely in patients undergoing microvascular breast reconstruction. The higher rate of bleeding in the postoperative group may be related to the onset of action of enoxaparin of 4 to 6 hours, which allows for intraoperative hemostasis in the preoperative group and possibly potentiating postoperative oozing when administered postoperatively. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Bassiri-Tehrani B, Karanetz I, Bernik SF, et al. The Timing of Chemoprophylaxis in Autologous Microsurgical Breast Reconstruction. Plast Reconstr Surg. 2018. PMID: 30511965. doi:10.1097/PRS.0000000000004825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。